在高能级国际合作平台方面，湖南省级国际科技创新合作基地建设成效显著。目前，该省已与超过100 个境外机构签署合作协议，累计申请专利2100余项，产生一批可转化重大成果，并通过技术转移、设备 引进等方式加速国际先进技术落地，深化科技产业融合。 中新网长沙1月27日电(向一鹏)湖南杂交水稻已在全球70多个国家推广种植800多万公顷，在非洲多个国 家试种成功。其中，马达加斯加实现杂交水稻商业化生产，平均每公顷增产3.5吨。 2025年，湖南加速融入全球创新网络，产生了包括杂交水稻在内的一系列标志性合作成果。湖南省科学 技术厅27日透露，截至目前，湖南科研合作"朋友圈"已拓展到130多个国家和地区。 据了解，湖南在埃及索哈杰建成装机容量6kW的离并网型光伏示范应用系统，有效缓解当地取水、用电 紧张问题，为区域能源保障提供实践样本。该省与德国弗劳恩霍夫应用研究促进协会合作开展可持续经 济型树脂体系研发，将大幅降低风机叶片的回收成本，助力汽车零部件、机车、低空飞行器等行业发 展。 拓展科研"朋友圈"，去年，湖南与英国励讯集团、北欧可持续发展协会等全球知名科研机构签订合作协 议，建立官方合作关系。此外，该省集聚全球智力资源 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [8]. Core Insights - The company is accelerating its international expansion, having licensed its innovative drug SHR-A1811 to Glenmark Specialty for an upfront payment of $18 million, with potential milestone payments and sales royalties totaling up to $1.093 billion. This marks the second significant overseas licensing deal for the company within the month [5][6]. - The drug SHR-A1811 has been approved for use in treating adult patients with HER2-mutated non-small cell lung cancer (NSCLC) and is the first Chinese-developed antibody-drug conjugate approved for this indication. The company is also pursuing new indications for breast cancer treatment [5]. - The company is enhancing its R&D capabilities and integrating into the global innovation network by collaborating with multinational pharmaceutical companies and innovative startups, aiming to maximize product value through international partnerships [5]. Financial Summary - The company’s projected financials for 2024 to 2027 show a steady increase in total revenue, from 27,985 million yuan in 2024 to 42,378 million yuan in 2027. Net profit is expected to rise from 6,337 million yuan in 2024 to 9,629 million yuan in 2027, with EPS projected to grow from 0.95 yuan in 2024 to 1.45 yuan in 2027 [6]. - The company’s return on equity (ROE) stands at 7.88%, with a market capitalization of 465.334 billion yuan and a closing price of 70.11 yuan as of September 24, 2025 [3][5].